Drug Profile
Research programme: immuno-inflammatory disorder therapeutics - Revolo Biotherapeutics
Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Peptinnovate
- Developer Revolo Biotherapeutics
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for clinical-Phase-Unknown development in Inflammation in United Kingdom (Parenteral)
- 05 Mar 2021 Immune Regulation is now called Revolo Biotherapeutics
- 17 Dec 2020 Clinical trials in Inflammation in United Kingdom (Parenteral)